IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤内科
学科主题临床医学
The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa
Song, Qingkun1; Zhou, Xinna1; Yu, Jing2; Dong, Ningning3; Wang, Xiaoli1; Yang, Huabing1; Ren, Jun1,4; Lyerly, H. Kim4
刊名SCIENTIFIC REPORTS
2015-11-25
DOI10.1038/srep16775
5
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
资助者Natural Science Foundation of China ; Suan G Komen for Cure Foundation ; Youth Foundation of Beijing Shijitan Hospital ; Natural Science Foundation of China ; Suan G Komen for Cure Foundation ; Youth Foundation of Beijing Shijitan Hospital
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]ANTHRACYCLINE-PRETREATED PATIENTS ; PHASE-II TRIAL ; LIVER METASTASES ; DRUG-THERAPY ; CAPECITABINE ; GEMCITABINE ; CYTOCHROME-P450 ; VINORELBINE ; SURVIVAL
英文摘要

This study investigated interactive effects of CYP2B6 genotypes and liver metastasis on the prognosis of metastatic breast cancer patients who received combined chemotherapy of docetaxel and thiotepa. Totally 153 patients were retrospectively genotyped rs8192719 (c.1294 53C >T) and rs2279343 (c.785A>G). Kaplan-Meier method and Cox Proportional Hazard Regression model were used to estimate the survival. Patients with liver metastasis had worsen prognosis, conferring a 2.26-fold high risk of progression and 1.93-fold high risk of death (p < 0.05). Both CT/TT genotype of rs8192719 (c.1294 53C >T) and AG genotype of rs2279343 (c.785A>G) prolonged survival (p < 0.05). Furthermore, among liver metastatic patients, AG genotype of rs2279343 (c.785A>G) was associated with a 47% reduced risk of death and a 6-month-longer overall survival (p < 0.05). Among non-liver metastatic patients, hazard ratios of CT/TT genotype of rs8192719 (c.1294 53C >T) were 0.45 for progression and 0.40 for death; and the corresponding survival was improved by 6 months and 16 months, respectively (p < 0.05). Genotypes of CYP2B6 had an interaction with clinical efficacy of docetaxel and thiotepa on metastatic breast cancer patients; and metastatic sites also affected clinical responses. Further therapies should take into account of chemotherapy regimen, genotypes of metabolizing enzymes and metastatic sites for the particular subpopulation.

语种英语
所属项目编号81172534 ; SPCHIN1201 ; 2013-q-04
资助者Natural Science Foundation of China ; Suan G Komen for Cure Foundation ; Youth Foundation of Beijing Shijitan Hospital ; Natural Science Foundation of China ; Suan G Komen for Cure Foundation ; Youth Foundation of Beijing Shijitan Hospital
WOS记录号WOS:000365274400001
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58229
专题北京大学临床肿瘤学院_肿瘤内科
作者单位1.Duke Univ, Dept Surg, Med Ctr, Durham, NC 27710 USA
2.Capital Med Univ, Beijing Shijitan Hosp, Beijing Key Lab Therapeut Canc Vaccines, Ctr Canc, Beijing 100038, Peoples R China
3.Peking Univ, Dept Med Oncol, Canc Hosp & Inst, Beijing 100142, Peoples R China
4.Capital Med Univ, Beijing Friendship Hosp, Dept Digest Dis, Beijing 100050, Peoples R China
推荐引用方式
GB/T 7714
Song, Qingkun,Zhou, Xinna,Yu, Jing,et al. The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa[J]. SCIENTIFIC REPORTS,2015,5.
APA Song, Qingkun.,Zhou, Xinna.,Yu, Jing.,Dong, Ningning.,Wang, Xiaoli.,...&Lyerly, H. Kim.(2015).The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.SCIENTIFIC REPORTS,5.
MLA Song, Qingkun,et al."The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa".SCIENTIFIC REPORTS 5(2015).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Song, Qingkun]的文章
[Zhou, Xinna]的文章
[Yu, Jing]的文章
百度学术
百度学术中相似的文章
[Song, Qingkun]的文章
[Zhou, Xinna]的文章
[Yu, Jing]的文章
必应学术
必应学术中相似的文章
[Song, Qingkun]的文章
[Zhou, Xinna]的文章
[Yu, Jing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。